Author

J. F. Woolley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. D. Duckworth· 2 shared J. R. Slupsky· 2 shared A. He· 1 shared A. Rashid· 1 shared C. A. Newell· 1 shared C. Eberlein· 1 shared C. J. Guidos· 1 shared C. M. P. Melo· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. Duckworth

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

P. T. Kennedy, E. L. Saulters, A. D. Duckworth, Y. J. Lim, J. F. Woolley, J. R. Slupsky, M. S. Cragg, F. J. Ward, L. N. Dahal

This study shows that soluble CTLA-4 suppresses T-cell activation and promotes tumor growth in mice, and that blocking sCTLA-4 enhances anti-tumor immunity.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

Development of a bispecific Antibody Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia

A. D. Duckworth, C. Eberlein, V. Pollard, R. Bethell, J. R. Slupsky, O. Schon, J. F. Woolley, T. Thorn

This paper develops a bispecific antibody-drug conjugate targeting CD7 and CD33 for AML treatment, showing improved selectivity and safety in preclinical studies.

bioRxiv · Jul 17, 2022 · PreprintCancer Biology

INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis

J. F. Woolley, K. Chen, G. T. Saffi, G. E. Genc, D. K. C. Lee, I. Dzneladze, R. He, J. T.-S. Chow, M. M. Gabra, M. H. Son, C. M. P. Melo, C. A. Newell, A. He, E. M. Schoof, S. Z. Xie, , L. Salmena

This study identifies INPP4B's role in promoting leukemic stem cell (LSC) survival by enhancing lysosome biogenesis, leading to poor AML prognosis and suggesting therapeutic targets.

bioRxiv · Mar 25, 2021 · PreprintCancer Biology